期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
表面应用FK506对全角膜移植免疫排斥的预防和治疗作用 被引量:5
1
作者 刘永民 陈家祺 《中国实用眼科杂志》 CSCD 北大核心 2007年第4期360-365,共6页
目的探讨FK506(他克莫司)滴眼液对全角膜移植免疫排斥的预防和治疗作用。方法对全角膜和亚全角膜受损毁的50眼进行全角膜移植。术后病人分两组,0.05%FK506滴眼液联合0.1%地塞米松滴眼液的FK506治疗组和1%环孢霉素A(cyclosporine A,CS... 目的探讨FK506(他克莫司)滴眼液对全角膜移植免疫排斥的预防和治疗作用。方法对全角膜和亚全角膜受损毁的50眼进行全角膜移植。术后病人分两组,0.05%FK506滴眼液联合0.1%地塞米松滴眼液的FK506治疗组和1%环孢霉素A(cyclosporine A,CSA)滴眼液联合0.1%地塞米松滴眼液的CSA治疗组,比较它们预防和治疗移植排斥的疗效。结果平均随访18.6m±6.2m(6~27m)。总的眼球保存率96%,角膜植片总透明率42.9%。术后,23眼视力超过0.02,3眼视力超过0.3,最好视力1.2。FK506组与CSA组相比,明显降低和推迟移植排斥(P=0.005和P=0.036)。FK506组最终视力和术后植片透明率均高于CSA组(P=0.001和P=0.017)。FK506组术后6m和12m的植片透明率分别是74.1%和60.5%,而CSA组分别是42.1%和24.1%。结论通过早期联合表面应用FK506和皮质类固醇,后期单独表面应用FK506,全角膜移植不仅可以挽救角膜和眼前段严重受损的眼球,而且使多数病人获得较好的视力。 展开更多
关键词 fk506(他克莫司) 全角膜移植 移植排斥 环孢霉素A(CSA)
原文传递
FK506(他克莫司)滴眼后在兔眼组织中的分布研究 被引量:2
2
作者 刘永民 陈家祺 《中国实用眼科杂志》 CSCD 北大核心 2007年第4期443-447,共5页
目的探讨FK506(他克莫司)滴眼液表面应用后在眼前段组织和房水中的分布。方法配制0.05%、0.1%、0.2%、0.4%FK506滴眼液。在滴眼后不同的时间点,应用酶联免疫测定法测定房水、角膜、结膜和虹膜中的FK506浓度。结果0.05%FK506,1h房水药... 目的探讨FK506(他克莫司)滴眼液表面应用后在眼前段组织和房水中的分布。方法配制0.05%、0.1%、0.2%、0.4%FK506滴眼液。在滴眼后不同的时间点,应用酶联免疫测定法测定房水、角膜、结膜和虹膜中的FK506浓度。结果0.05%FK506,1h房水药物浓度达到高峰,峰值是18.93±6.95ng/ml。0.1%FK506峰值在2h,房水药物浓度是28.33±9.31ng/ml。4种不同浓度的滴眼液滴眼后1h,结膜、角膜中的FK506浓度为43.52ng/g~123.35ng/g、虹膜中8.85ng/g~21.76ng/g、房水中18.90~33.55ng/ml。各种浓度滴眼液滴眼后2.5h,角膜中的FK506浓度为41.75ng/g~118.29ng/g,房水中为8.35ng/ml~27.85ng/ml,结膜和虹膜中的含量明显减少。结论我们配制的FK506滴眼液,具有良好的眼部穿透性,在房水、角膜和结膜中均可以达到有效的治疗浓度,可以用来治疗眼表或眼前段免疫相关性疾病。 展开更多
关键词 fk506(他克莫司) 分布 滴眼液 酶联免疫测定
原文传递
Use of FK506 and bone marrow mesenchymal stem cells for rat hind limb allografts 被引量:1
3
作者 Youxin Song Zhujun Wang +3 位作者 Zhixue Wang Hong Zhang Xiaohui Li Bin Chen 《Neural Regeneration Research》 SCIE CAS CSCD 2012年第34期2681-2688,共8页
Dark Agouti rat donor hind limbs were orthotopically transplanted into Lewis rat recipients to verify the effects of bone marrow mesenchymal stem cells on neural regeneration and functional recovery of allotransplante... Dark Agouti rat donor hind limbs were orthotopically transplanted into Lewis rat recipients to verify the effects of bone marrow mesenchymal stem cells on neural regeneration and functional recovery of allotransplanted limbs in the microenvironment of immunotolerance, bone marrow mesenchymal stem cells were intramuscularly (gluteus maximus) injected with FK506 (tacrolimus) daily, and were transplanted to the injured nerves. Results indicated that the allograft group not receiving therapy showed severe rejection, with transplanted limbs detaching at 10 days after transplantation with complete necrosis. The number of myelinated axons and Schwann cells in the FK506 and FK506 + bone marrow mesenchymal stem cells groups were significantly increased. We observed a lesser degree of gastrocnemius muscle degeneration, and increased polymorphic fibers along with other pathological changes in the FK506 + bone marrow mesenchymal stem cells group. The FK506 + bone marrow mesenchymal stem cells group showed significantly better recovery than the autograft and FK506 groups. The results demonstrated that FK506 improved the immune microenvironment. FK506 combined with bone marrow mesenchymal stem cells significantly promoted sciatic nerve regeneration, and improved sensory recovery and motor function in hind limb allotransplant. 展开更多
关键词 fk506 tacrolimus bone marrow mesenchymal stem cells allotransplant hind limb transplant function recovery sensory function motor function peripheral nerve injury REGENERATION neuralregeneration
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部